Belgian specialty pharma gains pediatric cancer franchise and FDA priority review voucher
Belgian specialty pharmaceutical company SERB Pharmaceuticals announced an all-cash $412 million acquisition of Y-mAbs Therapeutics, a pediatric cancer-focused biotech company.
The deal provides SERB with Y-mAbs’ commercial product Danyelza (naxitamab) for treating neuroblastoma, along with development programs in rare pediatric cancers. The acquisition includes Y-mAbs’ FDA priority review voucher, which can accelerate regulatory timelines for future products.
Strategic Value: SERB plans to leverage its global commercial footprint to expand Danyelza’s international reach, particularly in European and emerging markets where the treatment is not yet available. The priority review voucher adds significant strategic value for SERB’s broader pipeline.
The transaction reflects growing consolidation in rare disease markets, where specialized commercial capabilities command premium valuations due to the expertise required for success in small patient populations.
